Sars-CoV2: Clinical Trials

6 trials for Sars-CoV2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated. 6 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 36Terminated 6
Phase 23Terminated 3

Follow Sars-CoV2: new trials by email Literature Review of Sars-CoV2 trials Research Report on Sars-CoV2

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Linagliptin 5 MG - COVID 19, Coronavirus
Phase 3TerminatedRabin Medical Center642020-10-012021-06-02
Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients
BIO101, Placebo - Covid-19, SARS-CoV2
Phase 2 / Phase 3TerminatedBiophytis2382020-08-262026-08-12
Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19
Janus Kinase Inhibitor (ruxolitinib), Placebo - Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2
Phase 2 / Phase 3TerminatedVanderson Geraldo Rocha52020-08-142021-04-08
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
Hyperbaric oxygen - SARS (Severe Acute Respiratory Syndrome), Cytokine Storm
Phase 2 / Phase 3TerminatedKarolinska Institutet342020-06-032023-01-09
Preventing COVID-19 Complications With Low- and High-dose Anticoagulation
Enoxaparin - COVID, Sars-CoV2
Phase 3TerminatedUniversity Hospital, Geneva1602020-04-282021-09-14
Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients
Hydroxychloroquine (HCQ) - Sars-CoV2
Phase 3TerminatedCentre Hospitalier Universitaire de Saint Etienne72020-04-032020-09-07

Narrower conditions

COVID-19 (4)  ·  Coronavirus Infections (1)  ·  Cytokine Release Syndrome (1)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Endocrine System Diseases (1)  ·  Glucose Metabolism Disorders (1)  ·  Metabolic Diseases (1)  ·  Respiratory Distress Syndrome (1)  ·  Respiratory Tract Diseases (1)  ·  Severe Acute Respiratory Syndrome (1)  ·  Thrombosis (1)

Broader conditions

Coronaviridae Infections (4)  ·  Infections (4)  ·  Lung Diseases (4)  ·  Nidovirales Infections (4)  ·  Pneumonia (4)  ·  Pneumonia, Viral (4)  ·  RNA Virus Infections (4)  ·  Respiratory Tract Infections (4)  ·  Virus Diseases (4)  ·  Coronavirus Infections (3)  ·  Respiratory Tract Diseases (3)  ·  Cardiovascular Diseases (1)  ·  Embolism and Thrombosis (1)  ·  Inflammation (1)  ·  Nutritional and Metabolic Diseases (1)

Interventions

Enoxaparin (1)  ·  Heparin (1)  ·  Hydroxychloroquine (1)  ·  Hyperbaric Oxygenation (1)  ·  Janus Kinase Inhibitors (1)  ·  Linagliptin (1)  ·  ruxolitinib (1)

Sponsors

Biophytis (1)  ·  Centre Hospitalier Universitaire de Saint Etienne (1)  ·  Karolinska Institutet (1)  ·  Rabin Medical Center (1)  ·  University Hospital, Geneva (1)  ·  Vanderson Geraldo Rocha (1)

Countries

Brazil (2)  ·  France (2)  ·  Belgium (1)  ·  Germany (1)  ·  Israel (1)  ·  Puerto Rico (1)  ·  Sweden (1)  ·  Switzerland (1)  ·  United States (1)

Top investigators

Anders Kjellberg, MD (1)  ·  Capucine Morelot-Panzini, MD (1)  ·  Kenny Rodriguez-Wallberg, MD, PhD (1)  ·  Peter Lindholm, MD, PhD (1)

Results publications

PMID 32407672, PMID 33430924, PMID 33502773, PMID 34226219, PMID 35002970, PMID 35244208, PMID 37510965, PMID 38545090, PMID 39393522